Island Abbey Nutritionals and Somru Bioscience nominated for Innovation Excellence Awards at GCACC Awards
Two PEI Bioscience Cluster companies Island Abbey Nutritionals and Somru Bioscience have both been selected as finalists for the Greater Charlottetown Area Chamber of Commerce 2024 President’s Excellence Award in the category of Innovation Excellence. The Innovation Excellence Award, sponsored by BIOVECTRA, recognizes a business that has demonstrated outstanding performance and achievement through innovative and creative approaches, resulting in new or improved programs, products, services or initiatives. The finalists are: Island Abbey Nutritionals, Somru BioScience, and Check Point Software Technologies.
On Wednesday, January 24, 2024, the GCACC will host the 2024 President’s Excellence Awards at the Delta Hotel in Charlottetown. Sponsored by Atlantic Lottery, the Chamber’s biggest night of the year will recognize and celebrate twenty-six finalists across nine award categories.
“It’s an honour for us to host our business community for this prestigious awards night where we celebrate excellence, innovation, service, and workplace excellence for our community,” said Kim Griffin, GCACC President. “Our members are truly partners in prosperity for our community today and for the future.”
About Island Abbey Nutritionals
Island Abbey Nutritionals™ is an innovative food science company based out of Prince Edward Island, Canada. With an impressive library of proven formulations, our state-of-the-art facilities specialize in manufacturing technology for gummy and lozenge production. As industry leaders, we provide full contract manufacturing, bottling, and packaging capabilities for a variety of supplementary and natural health-focused dietary needs.
About Somru Bioscience
Somru Bioscience is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications. The company utilizes a unique and proprietary Somru™ technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays in a short period of time.